The View From the Target's Boardroom: Seagen's Sell-Side Process With Centerview

Every figure below comes from Seagen Inc.'s DEFM14A (definitive merger proxy), filed April 24, 2023 with the SEC (CIK 0001060736). Full source on SEC EDGAR.

Deal snapshot

The core sell-side job: prove you didn't leave money on the table

Every fairness process exists to answer one question a plaintiffs' lawyer will ask in a shareholder lawsuit six weeks after signing: did the board and its bankers do enough work, and is the price fair? Seagen's board answered that question the standard way, retain an independent advisor (Centerview), have Centerview evaluate the offer against multiple valuation methods, get a written fairness opinion, and build airtight deal protections that still leave a "fiduciary out" if a better offer shows up.

The proxy's own table of contents shows the anatomy of that process: Background of the Merger (pages 34-45, the full narrative of how the deal came together), Recommendation of the Board; Reasons for the Merger (pages 45-48), Opinion of Centerview Partners LLC (pages 48-55), and Interests of Directors and Executive Officers in the Merger (pages 58-62, the conflicts disclosure). That structure is close to universal in target-side proxies, you saw the same shape in our Rouse/BofA Merrill Lynch breakdown.

What the board actually voted on, and why the threshold matters

The vote required isn't a simple majority of shares present, it's a majority of all shares outstanding and entitled to vote. That's a materially higher bar: abstentions and broker non-votes count the same as a vote against, and any stockholder who fails to vote at all is functionally voting no. A sell-side board negotiating this kind of threshold (versus a lower "majority of votes cast" standard) is signaling, and locking in, real confidence that the deal will get done, because a high bar makes any late wobble in support far more dangerous to the transaction.

Centerview's opinion: what it does and doesn't cover

The engagement letter language is worth reading closely, because it defines the actual scope of a "fairness opinion," a phrase people often assume means more than it does. Centerview was asked to opine on one specific question: whether $229.00/share was fair, from a financial point of view, to Seagen's shareholders (excluding Pfizer, Seagen treasury shares, and dissenting shares).

Centerview's opinion did not address any other term or aspect of the merger agreement or the transaction, and does not constitute a recommendation to any Seagen stockholder as to how to vote. That's standard, but important: the fairness opinion is narrowly about price, not about deal structure, timing, closing risk, or whether selling at all was the right strategic call. Those broader judgments are the board's job, informed by, but not delegated to, the banker.

Locking in the deal: the voting agreement as a sell-side tool too

Interestingly, the Baker Bros. voting agreement (covered from Pfizer's side in our buy-side breakdown) cuts both ways. From Seagen's board's perspective, getting its largest sophisticated holder to commit ~25% of the vote before the deal is even announced publicly is a sell-side insurance policy against activist interference or a late "vote no and hold out for more" campaign, a real risk in biotech M&A where specialist funds sometimes push for a higher price rather than accept the first signed number.

The fiduciary out: how a "locked up" deal still stays honest

Seagen's board agreed to strict no-solicitation terms, it can't shop the company after signing. But the merger agreement carves out a superior proposal exception: if an unsolicited bidder shows up with a better offer that Seagen didn't go looking for, the board can engage, and can even terminate the Pfizer deal to accept it, as long as it pays the $1.646B termination fee and gives Pfizer a four-business-day match right first.

This is the standard sell-side balancing act: give the acquirer enough certainty to justify a rich premium, while preserving just enough optionality that the board isn't accused of contracting away its fiduciary duties. No competing bidder ultimately emerged for Seagen, but the mechanism existed and shaped the negotiation regardless.

Litigation: the predictable aftermath of every announced deal over a few billion dollars

By the time the definitive proxy was filed, four separate shareholder complaints had already been filed in the Southern District of New York, alleging the preliminary proxy's disclosures were materially incomplete and misleading. This is close to boilerplate in large public-company M&A now, plaintiffs' firms file "disclosure only" suits almost reflexively, seeking supplemental disclosures and a fee award rather than blocking the deal. Seagen's board treated the claims as without merit and proceeded, this is the normal, low-stakes version of merger litigation, distinct from the kind of substantive antitrust challenge that can actually kill a deal (see our JetBlue/Spirit failed-transaction breakdown).

Buy-side vs. sell-side, same deal, two different jobs